|
- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30437
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
<http://www.therapeuticsdaily.com ... ve&channelID=31>
NanoBio Launches Development Program for a Therapeutic Intranasal Vaccine for
the Treatment of Hepatitis B
From the PharmaLive.com News Archive - Apr. 19, 2010
NIH Grant Supports Research of Nanoemulsion-based Vaccine for Patients
Previously Infected
ANN ARBOR, Mich.--(BUSINESS WIRE)--Apr 19, 2010 - NanoBio® Corporation today
announced an initiative to develop an intranasal vaccine for the treatment of
hepatitis B (HBV). NanoBio and the University of Michigan's, Michigan
Nanotechnology Institute for Medicine and Biological Sciences received funding
through a Phase 1 Technology Transfer (STTR) award by the National Institutes
of Health (NIH), to evaluate a potential therapeutic intranasal vaccine for
the treatment of hepatitis B in patients. This development program represents
the first of several potential therapeutic vaccines in a significant extension
of NanoBio's vaccine platform.
Hepatitis B is an infection of the liver caused by the HBV virus. HBV is the
most common cause of chronic viral liver disease worldwide. More than 370
million people are chronically infected with hepatitis B, leading to nearly
one million deaths annually as a result of cirrhosis, and liver failure. HBV
is transferred via bodily fluids and blood, and is commonly spread through
sexual intercourse and intravenous drug use. Today, vaccinations are routinely
given to infants to prevent infection contributing to lower rates of incidence
in recent years. However, for patients previously infected, recurring
infection is a concern that cannot be mitigated with existing vaccines.
“Currently available HBV vaccines are effective prophylactics, but lack
therapeutic properties for those that are already infected,” said James R.
Baker, MD, CEO and founder of NanoBio. “This new intranasal vaccine would
have great value as a treatment to reduce the risk of HBV associated liver
diseases and deaths globally. The vaccine is also highly stable at room
temperature enabling storage without refrigeration, a factor of great
importance in the developing world.”
Through this project, NanoBio and University of Michigan teams will
demonstrate in animals the capabilities of a nanoemulsion-based HBV vaccine to
safely induce immune responses in the presence of confounding factors such as
kidney failure. This research is especially important as individuals with
kidney function deficiencies are at high risk for complications of HBV
infection when compared to normal individuals.
After successful completion of the preclinical studies funded by this STTR,
NanoBio plans to conduct a FDA-approved Phase 1 clinical trial to evaluate
safety, dose range, immunogenicity and preliminary efficacy against chronic
HBV in humans with kidney failure.
About NanoBio's Vaccine Platform
NanoBio's nanoemulsion-based, intranasal vaccines have elicited robust immune
responses in animals vaccinated against seasonal and pandemic influenza,
hepatitis B, RSV, HIV, pneumococcal, anthrax, smallpox and other diseases. The
company's NanoStat™ adjuvant platform technology has demonstrated numerous
potential advantages over traditional vaccines, including: the ability to
generate robust mucosal, systemic and cellular immunity; antigen-sparing
qualities; cross-protection against non-vaccinated strains; ability to
adjuvant multiple antigen types without inducing inflammation; thermally
stabilizing the vaccine; and removing the need for needles.
About NanoBio
NanoBio Corporation is a privately held biopharmaceutical company focused on
developing and commercializing dermatological products, anti-infective
treatments and intranasal vaccines derived from its patented NanoStat™
technology platform. The company's lead product candidates are treatments for
herpes labialis (licensed to GSK in the U.S. and Canada), onychomycosis, acne,
cystic fibrosis and a broad platform of intranasal vaccines. The company's
headquarters and laboratory facilities are located in Ann Arbor, Michigan.
Contact: NanoBio Corporation
John Coffey, 734-302-9107
Vice President, Business Development
[email protected]
or
Schwartz Communications
Stacey Holifield/Benjamin Navon, 781-684-0770
[email protected] |
-
总评分: 现金 + 10
查看全部评分
|
发表于 2010-4-22 20:50
那比中国的信的过~
